OIS@AAO 2017 Videos

Aura

Aura Biosciences Prepares for Phase IIa Trial

By Mario Admin | December 8, 2017

Aura Biosciences is preparing to conduct a Phase IIa trial of its light-activated AU-011 therapy for treatment of ocular melanoma, CEO Elisabet de los Pinos,…

Read More
GenSight

GenSight Presents ND4 Results

By Mario Admin | December 6, 2017

Presenting results from the initial Phase I/II mitochondrial gene therapy for ND4 Leber’s hereditary optic nerve (LHON), GenSight’s Barrett Katz, MD, chief medical officer, stressed…

Read More
TrueVision

TrueVision Creating Virtual Surgical Cockpit

By Mario Admin | December 5, 2017

The TrueVision “story” is one of digital surgery, which allows for overlays, incorporating robotics, and incorporation of preoperative diagnostics. It’s a “virtual surgical cockpit that…

Read More
Ivantis

Ivantis Preparing for US Commercialization of Hydrus

By Mario Admin | December 5, 2017

The minimally invasive glaucoma surgery (MIGS) market is expected to grow from about $164 million in 2017 to $521 million by 2022, Ivantis CEO and…

Read More
Istar

iStar Medical Developing NextGen MIGS Device

By Mario Admin | December 5, 2017

This privately held company has a “pipeline of products” to treat glaucoma, concentrating on the MINIject, a “next-generation” minimally invasive glaucoma surgery (MIGS) device. The…

Read More
Powervision

PowerVision Updates on OUS Trials

By Mario Admin | December 5, 2017

The FluidVision AIOL is the first “true shape-changing, fluid-driven intraocular lens (IOL),” according to PowerVision, which means it creates a continuously variable monofocal lens and…

Read More
Mynosys

Mynosys Updates on OUS Zepto Launch

By Mario Admin | December 5, 2017

Zepto – Mynosys’ capsulotomy device used in a one-time method – was launched in India, Australia, Germany, and the US in 2017. The US clinical…

Read More
Avedro

Avedro Updates On Plans to Treat the Cornea

By Mario Admin | December 5, 2017

Avedro uses noninvasive strengthening of the cornea with topical drops and photoactivation without surgery or implants to reshape the cornea through cross-linking. The two major…

Read More
Aciont

Aciont Working on Five-Minute Treatment

By Mario Admin | December 5, 2017

A five-minute noninvasive transscleral treatment: Aciont’s Visual XP is used to deliver molecules passively. Another treatment, Visual XI, is based on iontopheresis and enables the…

Read More
EyeGate

EyeGate Pharma Moving Fast Toward Commercialization

By Mario Admin | December 5, 2017

EyeGate Pharma is taking two technology platforms quickly through to commercialization, CEO Stephen From said. The first is a hyaluronic acid (HA) the company is…

Read More
Novaliq

Novaliq Set to `Transform Ocular Therapies’

By Mario Admin | December 5, 2017

Novaliq’s mission is to “transform ocular therapeutics” using a proprietary water-free platform to accomplish the goal. A key limitation of water-based technologies is bioavailability, which…

Read More
Bio-Tissue

Bio-Tissue Targeting Dry Eye with Prokera

By Mario Admin | December 5, 2017

Bio-Tissue is the pioneer of the birth tissue industry, said CTO Scheffer Tseng. Biotissue is cryopreserved, and boasts anti-inflammation, anti-scarring, anti-angiogenesis, and promotion of wound…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.